205 results on '"Meza, A."'
Search Results
2. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children’s Oncology Group
3. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
4. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.
5. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
6. IL-6 and PIM1 expression in renal cell carcinoma.
7. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.
8. Association between thymectomy and incidence of renal cell carcinoma (RCC).
9. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
10. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.
11. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
12. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy.
13. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
14. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).
15. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).
16. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
17. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).
18. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
19. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
20. Sociodemographic predictors of cannabis use among patients with cancer residing in states with legalized cannabis.
21. Out-of-pocket costs from cannabis use in patients during cancer treatment at a major U.S. cancer center.
22. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.
23. A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
24. Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.
25. Pharmaceutical industry payments to physicians for the promotion of cancer drugs.
26. Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.
27. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).
28. Clinicopathological features and management of patients with primary CNS lymphoma: Peruvian experience in two cancer centers.
29. Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.
30. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
31. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations
32. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC)
33. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC)
34. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations
35. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC)
36. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations
37. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi)
38. Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
39. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC)
40. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy
41. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens
42. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
43. Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
44. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
45. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.
46. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
47. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.
48. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
49. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
50. Targeting an IL-6/JAK/STAT/PIM1 pathway in renal cell carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.